Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for detection and treatment monitoring
US12282022B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2017 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Mar 13, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57492
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μ{umlaut over ({acute over (ι)})}, of plasma is described herein. This assay uses binding of gold nanospheres and nanorods with EV- and tumor-derived EV-specificities to produce a local plasmon effect that enhances tumor-derived EV detection sensitivity and specificity. This nPES approach is also a non-invasive method for assessing pancreatic cancer stage and treatment response that can be easily refined for clinical use, and is readily adapted for diagnosis and monitoring of other conditions with disease-specific EV proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.